ArticleJournal of orthopaedic translation2026
PLPP1 inhibits Wnt/β-catenin signaling via enhancing Caveolin-1/β-catenin interaction and is negatively regulated by c-Myc in osteosarcoma.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents, characterized by rapid progression and poor prognosis. The molecular mechanisms underlying OS malignancy remain incompletely understood. Phospholipid phosphatase 1 (PLPP1) has recently been implicated in cancer biology, yet its role in OS is largely unknown. Methods: RNA sequence data from TARGET-OS and GEO cohorts were downloaded and analyzed for assessing the relationship between PLPP1 expression levels and the OS prognosis. PLPP1 expression levels in OS cells and samples were detected using qRT-PCR, WB and immunohistochemistry. The effects of PLPP1 on proliferation, migration, invasion and chemosensitivity of OS cells were evaluated by up- or down-regulated PLLP1 expression. In Results: PLPP1 was markedly down-regulated in OS tissues and cell lines. And low expression level of PLPP1 was correlated with poor prognosis, advanced clinical stage and metastasis. Functionally, PLPP1 overexpression inhibited OS cell proliferation, migration, invasion, and enhanced chemotherapy-induced apoptosis; conversely, silencing PLPP1 produced the opposite effects. In Conclusions: This study identified PLPP1 as a prognostic suppressor in OS that inhibited β-catenin nuclear import through enhancing Caveolin-1/β-catenin interaction and was transcriptionally repressed by c-Myc. Targeting the c-Myc/PLPP1/β-catenin axis might represent a promising therapeutic strategy for OS. The translational potential of this article: This study revealed the potential of PLPP1 as a novel prognostic biomarker of OS, and suggested its potential for therapeutic applications by specifically activating PLPP1 expression using small-molecule activators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.